Clariane stock among the strongest declines in the SBF 120, -15% in one week

A decline of 2.88% that extends a fall of nearly 21% over three months

Clariane falls 2.88% to €3.31 during trading, ranking among the strongest declines in the SBF 120. Thursday's session had already been difficult for the stock, which now shows a decline of 15.17% over one week and 17.42% over one month. Over three months, the fall exceeds 20%, bringing the annual loss to more than 30%.

In this context of prolonged decline, the comparable group Emeis is following a similar path, falling 2.33% during trading. The Paris market, meanwhile, is up approximately 1% this morning, which makes Clariane's underperformance all the more visible within the index. The macroeconomic backdrop remains tense: the French 10-year OAT touched 4.90% on October 1st, at its highest level since 2002, amid budgetary uncertainty surrounding the 2027 budget bill project, whose adoption remains uncertain.

An RSI at 27 and a price well below all moving averages signal extreme selling pressure

The technical configuration of Clariane remains deteriorated across all moving average depths. The price at €3.31 is trading approximately 15% below the 20-day MA (€3.90), 16% below the 50-day MA (€3.96) and close to 16% below the 200-day MA (€3.94): these three moving averages are aligned at the same level, forming a coherent technical ceiling that the stock has been unable to recover since several weeks. The RSI at 27 reflects persistent selling pressure and a configuration close to oversold conditions, already observed during the October 1st session.

Resistance at €4.06 appears distant, and the price has clearly fallen back below the support level identified at €3.41. When the group published its first-half 2026 results on July 29th, it had mentioned an expected improvement in EBITDA margin of 100 to 150 basis points by end of 2026, while mentioning continued inflationary pressure on operating costs as one of the main risks.